Analyst Upgrade Sparks Interest: Recent analyst moves have drawn attention to Novo Nordisk shares, with one firm shifting its rating to Buy and raising its price target amid ongoing market consolidation.
Valuation Debates Heat Up: Social media chatter highlights the stock's compressed multiples around 10-14 times forward earnings, prompting views that the market may be overlooking long-term potential in its core therapies despite recent price weakness from prior peaks.
Sector Context Emerges: Discussions often tie the company to broader weight-management trends, noting partnerships and product positioning as factors that could support recovery if execution remains steady.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Revenue
Novo Nordisk had revenues of $15B in Q1 2026.
You can track NVO financials on Quiver Quantitative's NVO stock page.
You can access data on NVO stock through the Quiver Quantitative API.
Novo Nordisk Hedge Fund Activity
We have seen 570 institutional investors add shares of Novo Nordisk stock to their portfolio, and 902 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 19,333,750 shares (+inf%) to their portfolio in Q1 2026, for an estimated $693,211,606
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 9,884,077 shares (+808.8%) to their portfolio in Q1 2026, for an estimated $354,393,580
- FMR LLC removed 8,664,705 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $310,672,997
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 7,827,491 shares (+inf%) to their portfolio in Q1 2026, for an estimated $280,654,689
- TWO SIGMA INVESTMENTS, LP added 5,943,310 shares (+1731.8%) to their portfolio in Q1 2026, for an estimated $213,097,380
- GOLDMAN SACHS GROUP INC removed 5,865,741 shares (-53.4%) from their portfolio in Q1 2026, for an estimated $210,316,143
- BOSTON PARTNERS removed 5,231,804 shares (-97.3%) from their portfolio in Q1 2026, for an estimated $187,586,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
